LT2961426T - Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g - Google Patents
Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną gInfo
- Publication number
- LT2961426T LT2961426T LTEP14714815.9T LT14714815T LT2961426T LT 2961426 T LT2961426 T LT 2961426T LT 14714815 T LT14714815 T LT 14714815T LT 2961426 T LT2961426 T LT 2961426T
- Authority
- LT
- Lithuania
- Prior art keywords
- immunoglobulin
- treatment
- central nervous
- nervous diseases
- diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Microbiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361769673P | 2013-02-26 | 2013-02-26 | |
| US201361862814P | 2013-08-06 | 2013-08-06 | |
| PCT/US2014/018426 WO2014134070A1 (en) | 2013-02-26 | 2014-02-25 | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2961426T true LT2961426T (lt) | 2019-12-27 |
Family
ID=50424697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP14714815.9T LT2961426T (lt) | 2013-02-26 | 2014-02-25 | Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9556260B2 (https=) |
| EP (2) | EP2961426B1 (https=) |
| JP (1) | JP6379113B2 (https=) |
| AU (2) | AU2014223679B2 (https=) |
| DK (1) | DK2961426T3 (https=) |
| ES (1) | ES2759226T3 (https=) |
| HR (1) | HRP20192111T1 (https=) |
| HU (1) | HUE046752T2 (https=) |
| LT (1) | LT2961426T (https=) |
| PL (1) | PL2961426T3 (https=) |
| PT (1) | PT2961426T (https=) |
| SI (1) | SI2961426T1 (https=) |
| WO (1) | WO2014134070A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150100042A1 (en) * | 2013-10-07 | 2015-04-09 | Impel Neuropharma Inc. | Muroid Family Nasal Device |
| EP3129013A1 (en) * | 2014-04-10 | 2017-02-15 | Crowley, Patrick | Delivery of non-steroidal antiinflammatory agents to the brain via the nasal tract to treat neurological disorders |
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| US11331270B2 (en) | 2017-08-20 | 2022-05-17 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2020163815A1 (en) * | 2019-02-07 | 2020-08-13 | Innomed Technologies, Inc. | Ivig treatments for bell's palsy |
| WO2020263484A1 (en) * | 2019-06-28 | 2020-12-30 | Mayo Foundation For Medical Education And Research | Methods and materials for treating neuromyelitis optica spectrum diseases |
| KR20220047332A (ko) * | 2019-08-13 | 2022-04-15 | 알티뮨 인크. | 치료제 효과 및 이의 투여 경로 |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| EP3991573A1 (de) * | 2020-11-03 | 2022-05-04 | Patrick Faber | Zusammensetzungen zur nasalen applikation |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (https=) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| KR100390480B1 (ko) | 1995-01-23 | 2003-10-04 | 디렉트-할러 아/에스 | 흡입기 |
| NZ514442A (en) | 1999-03-03 | 2003-08-29 | Optinose As | Nasal delivery device |
| US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| US20070254889A1 (en) * | 2001-04-23 | 2007-11-01 | Lee-Way Jin | Compounds and methods useful for rescuing cells from beta-amyloid toxicity and treatment of Alzheimer's disease |
| CA2462682A1 (en) | 2001-10-04 | 2003-04-10 | Protein Therapeutics, Inc. | The use of gammaglobulin for the treatment of immune-mediated diseases |
| US20040101909A1 (en) | 2002-08-20 | 2004-05-27 | Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 | Purification of polyreactive autoantibodies and uses thereof |
| US20090136505A1 (en) | 2005-02-23 | 2009-05-28 | Johanna Bentz | Intranasal Administration of Active Agents to the Central Nervous System |
| NZ581205A (en) | 2005-02-23 | 2011-06-30 | Alza Corp | Intranasal administration of active agents to the central nervous system |
| US9084777B2 (en) * | 2005-12-28 | 2015-07-21 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing formulations |
| WO2007106617A2 (en) * | 2006-01-30 | 2007-09-20 | Talecris Biotherapeutics, Inc. | Method of treatment and prophylaxis of diseases related to amyloid deposition using igm |
| MX2008010612A (es) * | 2006-02-15 | 2009-03-20 | Ramot At Tel Aviv University | Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro. |
| EP2152240A4 (en) | 2007-06-08 | 2012-05-09 | Healthpartners Res Foundation | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR REINFORCED TARGETING OF THERAPEUTIC COMPOUNDS TO THE CENTRAL NERVOUS SYSTEM |
| AU2009222199A1 (en) * | 2008-02-29 | 2009-09-11 | Baxter Healthcare S.A. | Anti-amyloid beta activity of intravenous immunoglobulin (IVIG) in vitro |
| US8622993B2 (en) | 2009-12-18 | 2014-01-07 | Healthpartners Research Foundation | Device and method for delivering therapeutic substances to the maxillary sinus of a patient |
| DK2531218T3 (en) * | 2010-02-04 | 2019-04-01 | Csl Behring Ag | immunoglobulin |
| WO2011150284A2 (en) * | 2010-05-26 | 2011-12-01 | Baxter International Inc. | Removal of serine proteases by treatment with finely divided silicon dioxide |
-
2014
- 2014-02-25 JP JP2015559285A patent/JP6379113B2/ja active Active
- 2014-02-25 LT LTEP14714815.9T patent/LT2961426T/lt unknown
- 2014-02-25 WO PCT/US2014/018426 patent/WO2014134070A1/en not_active Ceased
- 2014-02-25 US US14/189,981 patent/US9556260B2/en active Active
- 2014-02-25 DK DK14714815T patent/DK2961426T3/da active
- 2014-02-25 HR HRP20192111TT patent/HRP20192111T1/hr unknown
- 2014-02-25 EP EP14714815.9A patent/EP2961426B1/en active Active
- 2014-02-25 HU HUE14714815A patent/HUE046752T2/hu unknown
- 2014-02-25 PL PL14714815T patent/PL2961426T3/pl unknown
- 2014-02-25 ES ES14714815T patent/ES2759226T3/es active Active
- 2014-02-25 SI SI201431417T patent/SI2961426T1/sl unknown
- 2014-02-25 PT PT147148159T patent/PT2961426T/pt unknown
- 2014-02-25 EP EP19197257.9A patent/EP3597220A1/en not_active Withdrawn
- 2014-02-25 AU AU2014223679A patent/AU2014223679B2/en active Active
-
2016
- 2016-10-26 US US15/335,027 patent/US10144776B2/en active Active
-
2018
- 2018-10-19 US US16/165,993 patent/US20190055307A1/en not_active Abandoned
- 2018-11-08 AU AU2018260883A patent/AU2018260883B2/en not_active Expired - Fee Related
-
2020
- 2020-12-14 US US17/121,553 patent/US11851481B2/en active Active
-
2023
- 2023-11-13 US US18/507,265 patent/US12503501B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140242067A1 (en) | 2014-08-28 |
| JP6379113B2 (ja) | 2018-08-22 |
| ES2759226T3 (es) | 2020-05-08 |
| EP3597220A1 (en) | 2020-01-22 |
| PT2961426T (pt) | 2019-12-09 |
| US12503501B2 (en) | 2025-12-23 |
| EP2961426B1 (en) | 2019-10-30 |
| AU2014223679A1 (en) | 2015-09-24 |
| SI2961426T1 (sl) | 2020-01-31 |
| DK2961426T3 (da) | 2019-12-02 |
| AU2014223679B2 (en) | 2018-11-29 |
| AU2018260883B2 (en) | 2020-08-06 |
| US9556260B2 (en) | 2017-01-31 |
| JP2016512490A (ja) | 2016-04-28 |
| EP2961426A1 (en) | 2016-01-06 |
| HUE046752T2 (hu) | 2020-03-30 |
| US20190055307A1 (en) | 2019-02-21 |
| AU2018260883A1 (en) | 2018-11-29 |
| HRP20192111T1 (hr) | 2020-03-20 |
| US11851481B2 (en) | 2023-12-26 |
| US20240117025A1 (en) | 2024-04-11 |
| WO2014134070A1 (en) | 2014-09-04 |
| US10144776B2 (en) | 2018-12-04 |
| US20210101967A1 (en) | 2021-04-08 |
| US20170044244A1 (en) | 2017-02-16 |
| PL2961426T3 (pl) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL268987B (en) | System for glaucoma treatment | |
| LTC2785706I2 (lt) | Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui | |
| LT2961426T (lt) | Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g | |
| HUE061618T2 (hu) | Vegyület szemrendellenességek kezelésére | |
| LT3010910T (lt) | Pirimidindiono junginiai, skirti širdies ligoms | |
| LT3556775T (lt) | Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui | |
| DK3110843T3 (da) | Kombinationsterapier med anti-cd38-antistoffer | |
| HRP20181679T1 (hr) | Amidni spojevi za liječenje hiv | |
| LT2981255T (lt) | Empagliflozino terapiniai panaudojimo būdai | |
| DK3311824T3 (da) | Cd47 målrettede terapier til behandlingen af infektionssygdomme | |
| DK2983787T3 (da) | Fremgangsmåde til behandling af posttraumatisk stresssygdom | |
| LT2885010T (lt) | Tautopatijos gydymo būdai | |
| LT2887944T (lt) | Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui | |
| HRP20190101T1 (hr) | Terapeutske uporabe empagliflozina | |
| PT3626270T (pt) | Tratamento de doenças cardiovasculares | |
| DK3065818T3 (da) | Anordning til behandling af sygdomme i centralnervesystemet ved hjælp af sansestimulering | |
| LT3007726T (lt) | Tautopatijos gydymo būdai | |
| LT3292875T (lt) | Kompozicijos ir būdai, skirti ligų gydymui | |
| LT2994160T (lt) | Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g | |
| DK2961378T3 (da) | Fremgangsmåder til behandlingen af mitochondrisk sygdom | |
| HUE044431T2 (hu) | Bakteriofág terápia | |
| HUS2000037I1 (hu) | Triazinok Protozoa okozta betegségek kezelésére | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| IL242220A0 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| SI2986325T1 (sl) | Postopki zdravljenja motenj ciklusa sečnine |